NDANASALSPRAY, METERED
Approved
Feb 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
4/8 — Partial
ALLERNAZE (triamcinolone acetonide) by Design Pharmaceuticals is clinical pharmacology: triamcinolone acetonide is a more potent derivative of triamcinolone. Approved for allergic rhinitis. First approved in 2000.
Drug data last refreshed Yesterday
Mechanism of Action
CLINICAL PHARMACOLOGY: Triamcinolone acetonide is a more potent derivative of triamcinolone. Triamcinolone acetonide is approximately eight times more potent than prednisone in animal models of inflammation. The clinical significance of this is unclear. Although the precise mechanism of…
Worked on ALLERNAZE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.